Allogene Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning. Thanks for joining us for another session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng, one of the Senior Biotech Analysts here at the firm. I'm joined by my associate Gensym losing the audience on stage, we have Allogene CEO, David Chang. I'll pass the mic to David briefly to for a short presentation, followed by a live Q&A either joining us live and you can some of the questions for the team through our conference portal. David, the stage is yours.
Brian, Happy New Year. And thanks for having me on podium today and for those who in the audience thanks for interest in what we are doing at Allogene. In a legal disclaimer and this is the beginning of the year. And this year, we have made some very important announcements about how we are redirecting our development program.
The four components of the announcements: one, advancing our lead program Cema-cel Cema cap
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
